# A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

> **NCT06518876** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Novatim Immune Therapeutics (Zhejiang) Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- POEMS Syndrome

## Interventions

- **BIOLOGICAL:** KQ-2003 CAR T-cells

## Key facts

- **NCT ID:** NCT06518876
- **Lead sponsor:** Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518876, "A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06518876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*